The EPS miss combined with withdrawn guidance and canceled earnings call is a major red flag. The May 7 announcement referenced in the filing is likely material and negative — traders should review that 8-K immediately. The stock is likely to sell off sharply on the EPS miss and uncertainty. Monitor for any further disclosures about the May 7 event.
Price Chart
Executive Summary
Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus estimate of $0.64 EPS and $148.2M revenue. The company withdrew forward guidance and canceled its earnings call following a May 7 announcement, creating significant uncertainty despite strong underlying product revenue growth from FIRDAPSE and AGAMREE.
Key Financial Metrics
Key Facts
- GAAP diluted EPS of $0.50 missed consensus estimate of $0.64 by 21.9%
- Total revenue of $149.4M was slightly above consensus of $148.2M (beat by 0.8%)
- Non-GAAP diluted EPS of $0.79 was reported, but Street consensus tracks GAAP EPS for pharma
- FIRDAPSE revenue grew 18.1% YoY to $98.9M; AGAMREE grew 66.6% to $36.7M
- FYCOMPA revenue declined 61.3% YoY to $13.8M following loss of exclusivity
- Company withdrew forward-looking guidance and canceled earnings call citing May 7 announcement
- Cash and equivalents of $755.9M with no funded debt as of March 31, 2026
- GAAP net income grew 12.3% YoY to $63.7M; operating income grew 15.6% to $73.2M
Financial Impact
GAAP diluted EPS of $0.50 vs $0.64 consensus (-21.9% miss); revenue $149.4M vs $148.2M consensus (+0.8% beat)
Risk Factors
- Withdrawn guidance and canceled earnings call signal significant uncertainty
- FYCOMPA revenue decline of 61.3% YoY due to loss of exclusivity may accelerate
- May 7 announcement could involve regulatory, legal, or operational setback
- EPS miss of 21.9% vs consensus undermines credibility of prior guidance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access